Christopher Heaphy, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

PhD, University of New Mexico School of Medicine

Dr. Christopher Heaphy is a cancer biologist that has been conducting basic and translational studies focused on elucidating the role of telomere alterations across a range of cancer types (e.g. prostate, breast, brain, pancreatic, ovarian). Overall, his research program uses a combination of tissue-based, cell-based, and molecular approaches to study normal and abnormal telomere biology as it relates to cancer initiation and progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype – a telomerase-independent telomere maintenance mechanism. In addition, his laboratory focuses on how these findings may be readily translated into accurately predicting cancer risk, early detection, prognosis, and potential response to targeted therapies. Dr. Heaphy received his Ph.D. from the University of New Mexico School of Medicine and did his postdoctoral training at the Johns Hopkins University School of Medicine. He is currently affiliated with Boston Medical Center and is a member of the Boston University-Boston Medical Center (BU-BMC) Cancer Center.

Boston University
BU-BMC Cancer Center

Boston University
Evans Center for Interdisciplinary Biomedical Research

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences

Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy
01/01/2021 - 12/31/2022 (PI)
Johns Hopkins University National Cancer Inst


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Yuan M, Eberhart CG, Pratilas CA, Blakeley JO, Davis C, Stojanova M, Reilly K, Meeker AK, Heaphy CM, Rodriguez FJ. Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. Cancers (Basel). 2022 Jun 19; 14(12). PMID: 35740680; PMCID: PMC9221513; DOI: 10.3390/cancers14123015;
  2. Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2022 Apr 14; 28(8):1737. PMID: 35419593
  3. Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015.View Related Profiles. PMID: 35403746
  4. Lally SE, Milman T, Orloff M, Dalvin LA, Eberhart CG, Heaphy CM, Rodriguez FJ, Lin CC, Dockery PW, Shields JA, Shields CL. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology. 2022 Jun; 129(6):679-693. PMID: 35085662
  5. Dreijerink KM, Hackeng WM, Singhi AD, Heaphy CM, Brosens LA. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol. 2022 02; 256(2):143-148. PMID: 34750813
  6. Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proc Natl Acad Sci U S A. 2021 08 10; 118(32). PMID: 34341114; PMCID: PMC8364155; DOI: 10.1073/pnas.2018976118;
  7. Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol. 2021 11; 129(11):841-843. PMID: 34242496
  8. Kang HJ, Oh JH, Kim YW, Kim W, An J, Sung CO, Kim J, Shim JH, Hwang S, Yu E, Heaphy CM, Hong SM. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int. 2021 10; 41(10):2499-2510. PMID: 34036718
  9. Brosnan-Cashman JA, Davis CM, Diplas BH, Meeker AK, Rodriguez FJ, Heaphy CM. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Mod Pathol. 2021 10; 34(10):1810-1819. PMID: 34103668
  10. Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022 May; 71(5):961-973. PMID: 33849943; PMCID: PMC8511349; DOI: 10.1136/gutjnl-2020-322595;
Showing 10 of 96 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 96 publications over 19 distinct years, with a maximum of 11 publications in 2020


2022 North American Neuroendocrine Tumor Society (NANETS): Chair of the Scientific Review & Research Committee
2022 Endocrine-Related Cancer: Editorial Board Member
2021 Shipley Prostate Cancer Research Center at BU: Executive Advisory Committee Member
2021 North American Neuroendocrine Tumor Society (NANETS): Co-Chair of the Scientific Review & Research Committee
2021 Boston University: CTSI Pilot Grant Awardee
2021 Johns Hopkins University School of Medicine: Adjunct Assistant Professor in Oncology Center
2020 BU-BMC Cancer Center: American Cancer Society BU-BMC Cancer Center Pilot and Feasibility Program Awardee
2020 Boston University School of Medicine: Shipley Prostate Cancer Pilot Grant Awardee
2019 95th Annual American Association of Neuropathologists Meeting: Moore Award for the Best Clinico-Pathologic Paper in Neuropathology
2016 North American Neuroendocrine Tumor Society: Basic/Translational Science Investigator Award
2014 Patrick C. Walsh Prostate Cancer Research Fund: Dr. and Mrs. Peter S. Bing Scholar Award
2014 Prostate Cancer Foundation: Young Investigator Award
2013 Johns Hopkins Department of Pathology Young Investigator’s Day: Award for Excellence in Translational Research
2012 Johns Hopkins Fellow Research Day: 1st Place for Basic Research
2011 Johns Hopkins Department of Pathology Young Investigator’s Day: Award for Excellence in Translational Research
2011 United States and Canadian Academy of Pathology: Stowell-Orbison Award
2002 National Cancer Institute: Cancer Research Training Fellowship; Laboratory of Cellular Carcinogenesis and Tumor Promotion
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Alternative lengthening of telomeres
Tissue-based biomarkers

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')
  • Phone (see 'Contact Info')
Heaphy's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department